Document is current

Article History

Received: 2 June 2022

Accepted: 15 August 2022

First Online: 29 August 2022

Declarations

:

: Research for this study was done following the ethical guidelines of Finnish National Board on Research Integrity TENK . A statement on this was provided by the Finnish Institute of Bioethics. A written informed consent form was signed by the interviewees at the start of the interview. The citations of the particular interviewee together with the preceding paragraph of each citation were sent to the interviewees.

: <i>Eeva Ollila</i> employed by the Cancer Society of Finland, an organisation that also serves as an umbrella non-governmental organisation for several cancer patient organisations. This study was funded by the Cancer society of Finland. No other financial conflicts of interest to declare. <i>Vesa Kataja</i> is a member of the Pharmaceutical Pricing Board (PPB) Scientific Advisory Committee since 2013 and continuing, Member of the National Health Care Services Evaluating Board (Cohere) 2014–16, and Member of the National Health Care Services Evaluating Board (Cohere) Section for Evaluating Medicinal Products since 2017 and continuing. Kataja was the Chief Medical Director of Central Finland Health Care District 2014–2020, while as per position, also the Chair for the hospital Medicines Evaluating Board. No financial interests to declare. <i>Liisa Sailas</i> is member of the medicine’s advisory board of the Siun sote—Joint municipal authority for North Karelia social and health services since 2018, and of the medicinal assessment board of the Kuopio University hospital area since 2022. No financial conflicts of interest to declare.